1. 1 Aventis Pharma

2. 2 Prescription drugs Aventis Pharma Vaccines Aventis Pasteur Therapeutic proteins Aventis Behring Diagnostics Dade Behring

3. 3 Key Figures 92, 500 employees – 80% in Pharma 16 Bn€ Pharma sales – 5th in top 10 Strong & growing US presence with >35% sales 19,000 member sales force 16.8% R&D expenditure; 6500 scientists & technicians worldwide 15% of R&D expenditure dedicated to alliances; about 50 major biotech collaborations; about 250 academic collaborations

4. 4 Drug Innovation & Approval (R&D) Disease Groups supported by powerful technology platforms Gene Therapy * -CV - Metabolic Diseases, - Osteoarthritis, Thrombosis US FRANCE GERMANY JAPAN Global and US Drug Devt Ctr - Immunology platform - Respiratory diseases - RA - CNS European Drug Devt Ctr Asian Drug Devt Ctr - Oncology, - Infectious Diseases - Neurodegenerative Diseases, (Parkinson & Alzheimer), ~6500 scientists & technicians worldwide

5. 5 Drug Innovation & Approval in France 5 km CDG Airport ESSONNE VAL DE MARNE HAUTS DE SEINE PARIS SEINE ST DENIS Romainville Vitry-Alfortville Croix de Berny Evry Paris Research Centre European Drug Devt Centre ~2800 scientists & technicians

6. 6 New drug discovery technologies Candidate Identification Lead Identification Target Selection Preclinical Candidate Identification PhI / IIaPhIIbPhIIIRegulatory Review Functional Genomics Technologies DNA chips Proteomics, cellular & animal models.. Lead Identification Technologies MedChem, ChemBiol, Structural Genomics and Biology…. Technologies for Exploratory Development eADMET, TGX, PGX, Biomarkers…. Technologies for Global Rapid submissions e-submissions….. Integrated Data and Knowledge Management

7. 7 Integration of Genomics Technologies & Disease Biology Platforms Genomics Technology Platforms Aventis Genomics Centers Disease Biology Platforms Metabolism Oncology CNS / ND Cardiovascular Rheumatoid Arthritis Osteoarthritis - DJD Respiratory Diseases Anti-Infectives Immunology platform External Collaborations & Networks Targets relevant to disease

8. 8 Key Challenges The post-human genome sequence race functional genomics proteomics protein structure prediction re-thinking chemical approaches re-thinking clinical development Continuous integration of technologies (alliances and partnering), information and knowledge (knowledge networks) Availability of skilled work force (right skill-set and mind-set)

9. 9 In partnership with the European Commission: 12 Marie Curie Industry Host Fellowships for a 2 year period. Post-doc Opportunities in Aventis Pharma, France Parkinson’s Disease Gene Targets (3 positions) Molecular Modeling and High Throughput Medicinal Chemistry (3 positions) From Protein-Protein Interactions (yeast 2H) to Lead Discovery Process (3positions) Cardiovascular Gene Therapy (1 position) Adenoviral Vector-based system for Functional Genomics (1 position) Bio-Informatics in Toxicogenomics (1 position) Immediate Starting Date

10. 10 In partnership with the European Commission Post-doc Opportunities in Aventis Pharma, France The position are open to members of the E.C. or resident of associated countries for more than 5 years. The age limit at the time of selection is 35 years old. Austria, Belgium, Bulgaria, Czech republic, Denmark, Estonia, Finland, Germany Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Liechtenstein Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Republic of Cyprus, Romania Slovakia, Slovenia, Sweden, Spain, United Kingdom However French citizens are ineligible as well as those who have been resident in France for more than 12 out of the last 24 months.

11. 11 Coming soon 9 post-doctoral positions Post-doc Opportunities in Aventis Pharma, France Kinases in Oncology and Neurodegenerative diseases Gene Transfer in Angiogenesis Genomic Studies for the glial-neuronal interactions Statistics for Pharmacogenetics

12. 12 Post-doc Opportunities in Aventis Pharma, France 250 KF/year (38KEuros/year) Social security included 26 + 12 days holiday Project Team Networking Publications/patents Confidentiality

13. 13 Come and join us on the Aventis stand to learn more about our post-doctoral opportunities ! edith.heuillet@aventis.com